Rheumatoid Arthritis Therapeutics Market Size, Share and Industry Analysis By Product Type (Biologics, Non-Biologics), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast 2018-2025

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Pipeline Analysis

4.2 Regulatory Scenario for Key Countries

4.3 Pricing Analysis

4.4 Key Industry Developments-Mergers, Acquisitions, and Partnerships

4.5 Incidence & Prevalence of Rheumatoid Arthritis, By Key Countries

4.6 Snapshot of The Novel & Upcoming Therapies

4.7 An Overview of Treatment Plans For Rheumatoid Arthritis

5. Global Rheumatoid Arthritis Therapeutics Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Product

5.2.1 Biologics

5.2.2 Non-Biologics

5.2.2.1 NSAIDs

5.2.2.2 DMARDs

5.2.2.3 Others

5.3. Market Analysis, Insights and Forecast – By Distribution Channel

5.3.1 Hospital Pharmacy

5.3.2 Retail Pharmacy

5.3.3 Online Pharmacy

5.4. Market Analysis, Insights and Forecast – By Region

5.4.1 North America

5.4.2 Europe

5.4.3 Asia Pacific

5.4.4 Latin America

5.4.5 Middle East & Africa

6. North America Rheumatoid Arthritis Therapeutics Market Analysis, Insights and Forecast,2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis – By Product

6.2.1 Biologics

6.2.2 Non-Biologics

6.2.2.1 NSAIDs

6.2.2.2 DMARDs

6.2.2.3 Others

6.3. Market Analysis – By Distribution Channel

6.3.1 Hospital Pharmacy

6.3.2 Retail Pharmacy

6.3.3 Online Pharmacy

6.4. Market Analysis – By Country

6.4.1 U.S.

6.4.2 Canada

7. Europe Rheumatoid Arthritis Therapeutics Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis – By Product

7.2.1 Biologics

7.2.2 Non-Biologics

7.2.2.1 NSAIDs

7.2.2.2 DMARDs

7.2.2.3 Others

7.3. Market Analysis – By Distribution Channel

7.3.1 Hospital Pharmacy

7.3.2 Retail Pharmacy

7.3.3 Online Pharmacy

7.4. Market Analysis – By Country/Sub-region

7.4.1 U.K

7.4.2 Germany

7.4.3 France

7.4.4 Italy

7.4.5 Spain

7.4.6 Scandinavia

7.4.7 Rest of Europe

8. Asia Pacific Rheumatoid Arthritis Therapeutics Market Analysis, Insights and Forecast,2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis – By Product

8.2.1 Biologics

8.2.2 Non-Biologics

8.2.2.1 NSAIDs

8.2.2.2 DMARDs

8.2.2.3 Others

8.3. Market Analysis – By Distribution Channel

8.3.1 Hospital Pharmacy

8.3.2 Retail Pharmacy

8.3.3 Online Pharmacy

8.4. Market Analysis – By Country/Sub-region

8.4.1 China

8.4.2 Japan

8.4.3 India

8.4.4 Australia

8.4.5 Southeast Asia

8.4.6 Rest of Asia Pacific

9. Latin America Rheumatoid Arthritis Therapeutics Market Analysis, Insights and Forecast,2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis – By Product

9.2.1 Biologics

9.2.2 Non-Biologics

9.2.2.1 NSAIDs

9.2.2.2 DMARDs

9.2.2.3 Others

9.3. Market Analysis – By Distribution Channel

9.3.1 Hospital Pharmacy

9.3.2 Retail Pharmacy

9.3.3 Online Pharmacy

9.4. Market Analysis – By Country/Sub-region

9.4.1 Brazil

9.4.2 Mexico

9.4.3 Rest of Latin America

10. Middle East &Africa Rheumatoid Arthritis Therapeutics Market Analysis, Insights andForecast, 2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis – By Product

10.2.1 Biologics

10.2.2 Non-Biologics

10.2.2.1 NSAIDs

10.2.2.2 DMARDs

10.2.2.3 Others

10.3. Market Analysis – By Distribution Channel

10.3.1 Hospital Pharmacy

10.3.2 Retail Pharmacy

10.3.3 Online Pharmacy

10.4. Market Analysis – By Country/Sub-region

10.4.1 GCC Countries

10.4.2 South Africa

10.4.3 Rest of Middle East & Africa

11. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2017)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 AbbVieInc.

11.5.2 PfizerInc.

11.5.3 AmgenInc.

11.5.4 Johnson& Johnson Services, Inc.

11.5.5 CELGENE CORPORATION

11.5.6 Bristol-Myers Squibb Company

11.5.7 F.Hoffmann-La Roche AG

11.5.8 UCBS.A.

11.5.9 UCBS.A.

11.5.10 Gilead Sciences, Inc.

11.5.11 Other Prominent Market Players

 

12. Strategic Recommendations